Protalex Inc (PRTX) 5.7600 $PRTX
Protalex to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Thu Sep 04, 3:05PM CDT
Protalex, Inc. (OTCBB
RTX), a clinical-stage biopharmaceutical company, today announces its participation in the Rodman & Renshaw Annual Global Investment Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City.
Protalex Announces Acceptance of Abstract Highlighting Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients at the 2014 American College of Rheumatology Annual Meeting
Business Wire - Wed Sep 03, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was accepted for poster presentation at the upcoming American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014 being held in Boston, Massachusetts from November 14-19, 2014. The abstract will be available at the ACR's website at http://www.acrannualmeeting.org and on the Company's website at www.protalex.com.
Protalex Announces Data from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients Presented at the 2014 EULAR Annual European Congress of Rheumatology
Business Wire - Fri Jun 13, 5:30AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was highlighted in a poster presentation at EULAR's Annual European Congress of Rheumatology being held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is now available on EULAR's website at www.eular.org and the complete poster is available on the Company's website at www.protalex.com.
Protalex Announces Interim Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Mon Feb 10, 1:00PM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced preliminary findings from a limited interim analysis of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study). PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The interim analysis included patients in the first four dosing cohorts of the five-cohort study through day 85 of the study protocol.
Protalex Announces Appointment of Marco M. Elser to Its Board of Directors
Business Wire - Wed Feb 05, 7:30AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that Marco M. Elser has been appointed to its Board of Directors. Mr. Elser is a partner with AdviCorp Plc, a London-based investment banking firm. Mr. Elser's appointment fills the vacancy on the Board resulting from the untimely passing of John Doherty last month. Mr. Doherty was a co-founder of Protalex and served as a director and a member of its Scientific Advisory Board since November 2009.
Protalex Announces Completion of $2.8 Million Private Placement
Business Wire - Thu Jan 23, 7:00AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that it has consummated a private placement financing to accredited investors of 471,334 shares of its common stock at $6.00 per share, yielding gross proceeds of $2,828,000. No commissions were payable in connection with the financing transaction. Proceeds of the financing will be used for working capital purposes, principally to fund ongoing clinical trials and studies and related activities. The investors in the offering were granted piggy-back registration rights in connection with certain registration statements filed by the company, subject to certain exceptions, including a registration statement filed in connection with a primary offering by the company.
Protalex to Present at the Rodman & Renshaw 15th Annual Healthcare Conference
Business Wire - Thu Sep 05, 7:00AM CDT
Protalex, Inc. (OTCBB RTX), a clinical-stage biopharmaceutical company, today announces its participation in the Rodman & Renshaw 15th Annual Healthcare Conference, to be held September 9-10, 2013 at the Millennium Broadway Hotel in New York City.
OTC Daily Alert Stock Watch - Protalex, Inc (OTCQB: PRTX)
WorldStockWire - Fri Aug 16, 3:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Protalex Announces PRTX-100 Phase I Data Published in The Journal of Clinical Pharmacology
Business Wire - Thu Aug 15, 12:57PM CDT
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced publication of the Company's Phase 1 study with PRTX-100 in healthy volunteers. This article entitled, "Safety, Pharmacokinetic, Immunogenicity, and Pharmacodynamic Responses in Healthy Volunteers Following a Single Intravenous Injection of Purified Staphylococcal Protein A," appears in the Journal of Clinical Pharmacology, Volume 53 (9).
Protalex Receives Third Interim Review from Independent Data Safety Monitoring Committee in its Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis
Business Wire - Tue Jul 23, 8:25AM CDT
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Independent Data Safety Monitoring Committee (SMC), the Company is continuing enrollment in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). PRTX-100 is a candidate drug incorporating a highly-purified form of Staphylococcal Protein A.
Protalex to Continue Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review
Business Wire - Thu Mar 07, 9:15AM CST
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Data Safety Monitoring Committee, the Company is continuing enrollment and dosing of patients in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate and leflunomide in adults with active rheumatoid arthritis (RA). The dose of PRTX-100 for patients in the current treatment group (6.0 micrograms/kg) is four times that of the initial starting dosage (1.5 micrograms/kg).
Protalex to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Thu Sep 04, 3:05PM CDT
Protalex, Inc. (OTCBB
RTX), a clinical-stage biopharmaceutical company, today announces its participation in the Rodman & Renshaw Annual Global Investment Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. Protalex Announces Acceptance of Abstract Highlighting Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients at the 2014 American College of Rheumatology Annual Meeting
Business Wire - Wed Sep 03, 7:00AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was accepted for poster presentation at the upcoming American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting 2014 being held in Boston, Massachusetts from November 14-19, 2014. The abstract will be available at the ACR's website at http://www.acrannualmeeting.org and on the Company's website at www.protalex.com. Protalex Announces Data from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients Presented at the 2014 EULAR Annual European Congress of Rheumatology
Business Wire - Fri Jun 13, 5:30AM CDT
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was highlighted in a poster presentation at EULAR's Annual European Congress of Rheumatology being held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is now available on EULAR's website at www.eular.org and the complete poster is available on the Company's website at www.protalex.com. Protalex Announces Interim Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Mon Feb 10, 1:00PM CST
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, today announced preliminary findings from a limited interim analysis of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study). PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The interim analysis included patients in the first four dosing cohorts of the five-cohort study through day 85 of the study protocol. Protalex Announces Appointment of Marco M. Elser to Its Board of Directors
Business Wire - Wed Feb 05, 7:30AM CST
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, today announced that Marco M. Elser has been appointed to its Board of Directors. Mr. Elser is a partner with AdviCorp Plc, a London-based investment banking firm. Mr. Elser's appointment fills the vacancy on the Board resulting from the untimely passing of John Doherty last month. Mr. Doherty was a co-founder of Protalex and served as a director and a member of its Scientific Advisory Board since November 2009. Protalex Announces Completion of $2.8 Million Private Placement
Business Wire - Thu Jan 23, 7:00AM CST
Protalex, Inc. (OTCQB
RTX), a clinical-stage biopharmaceutical company, today announced that it has consummated a private placement financing to accredited investors of 471,334 shares of its common stock at $6.00 per share, yielding gross proceeds of $2,828,000. No commissions were payable in connection with the financing transaction. Proceeds of the financing will be used for working capital purposes, principally to fund ongoing clinical trials and studies and related activities. The investors in the offering were granted piggy-back registration rights in connection with certain registration statements filed by the company, subject to certain exceptions, including a registration statement filed in connection with a primary offering by the company. Protalex to Present at the Rodman & Renshaw 15th Annual Healthcare Conference
Business Wire - Thu Sep 05, 7:00AM CDT
Protalex, Inc. (OTCBB
RTX), a clinical-stage biopharmaceutical company, today announces its participation in the Rodman & Renshaw 15th Annual Healthcare Conference, to be held September 9-10, 2013 at the Millennium Broadway Hotel in New York City. OTC Daily Alert Stock Watch - Protalex, Inc (OTCQB: PRTX)
WorldStockWire - Fri Aug 16, 3:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Protalex Announces PRTX-100 Phase I Data Published in The Journal of Clinical Pharmacology
Business Wire - Thu Aug 15, 12:57PM CDT
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced publication of the Company's Phase 1 study with PRTX-100 in healthy volunteers. This article entitled, "Safety, Pharmacokinetic, Immunogenicity, and Pharmacodynamic Responses in Healthy Volunteers Following a Single Intravenous Injection of Purified Staphylococcal Protein A," appears in the Journal of Clinical Pharmacology, Volume 53 (9).
Protalex Receives Third Interim Review from Independent Data Safety Monitoring Committee in its Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis
Business Wire - Tue Jul 23, 8:25AM CDT
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Independent Data Safety Monitoring Committee (SMC), the Company is continuing enrollment in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). PRTX-100 is a candidate drug incorporating a highly-purified form of Staphylococcal Protein A.
Protalex to Continue Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review
Business Wire - Thu Mar 07, 9:15AM CST
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Data Safety Monitoring Committee, the Company is continuing enrollment and dosing of patients in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate and leflunomide in adults with active rheumatoid arthritis (RA). The dose of PRTX-100 for patients in the current treatment group (6.0 micrograms/kg) is four times that of the initial starting dosage (1.5 micrograms/kg).
